Anas Nourelden

Dr. Anas Nourelden

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2023 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
AMAli Mir
Ali Mir
YBYasra Badi
Yasra Badi
SBSeif Bugazia
Seif Bugazia
ANAnas Nourelden
Anas Nourelden
AFAhmed Hashem Fathallah
Ahmed Hashem Fathallah
ZBZachary L. Brumberger
Zachary L. Brumberger
Background: Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or precluding chemotherapy entirely. Prior studies have suggested that using common cardioprotective agents may attenuate chemotherapy-induced cardiotoxicity. However, small sample sizes and conflicting outcomes have limited the clinical significance of these results. Hypothesis: A comprehensive network meta-analysis using updated and high-quality data can provide more conclusive information to assess which drug or drug class has the most significant effect in the management of chemotherapy-induced cardiotoxicity. Methods: We performed a literature search for randomized controlled trials (RCTs) investigating the effects of cardioprotective agents in patients with chemotherapy-induced cardiotoxicity. We used established analytical tools (netmeta package in RStudio) and data extraction formats to analyze the outcome data. To obviate systematic bias in the selection and interpretation of RCTs, we employed the validated Cochrane risk-of-bias tools. Agents included were statins, aldosterone receptor antagonists (MRAs), ACEIs, ARBs, and beta-blockers. Outcomes examined were improvement in clinical and laboratory parameters of cardiac function including a decreased reduction in left ventricular ejection fraction (LVEF), clinical HF, troponin-I, and B-natriuretic peptide levels. Results: Our study included 33 RCTs including a total of 3,285 patients. Compared to control groups, spironolactone therapy was associated with the greatest LVEF improvement (Mean difference (MD) = 12.80, [7.90; 17.70]), followed by enalapril (MD = 7.62, [5.31; 9.94]), nebivolol (MD = 7.30, [2.39; 12.21]), and statins (MD = 6.72, [3.58; 9.85]). Spironolactone was also associated with a significant reduction in troponin elevation (MD = − 0.01, [− 0.02; − 0.01]). Enalapril demonstrated the greatest BNP reduction (MD = − 49.00, [− 68.89; − 29.11]), which was followed by spironolactone (MD = − 16.00, [− 23.9; − 8.10]). Additionally, patients on enalapril had the lowest risk of developing clinical HF compared to the control population (RR = 0.05, [0.00; 0.75]). Conclusion: Our analysis reaffirmed that statins, MRAs, ACEIs, and beta-blockers can significantly attenuate chemotherapy-induced cardiotoxicity, while ARBs showed no significant effects. Spironolactone showed the most robust improvement of LVEF, which best supports its use among this population. Our analysis warrants future clinical studies examining the cardioprotective effects of cardiac remodeling therapy in cancer patients treated with chemotherapeutic agents.

21 July 2020 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
PDF file
YAYossef Hassan AbdelQadir
Yossef Hassan AbdelQadir
AHAboalmagd Hamdallah
Aboalmagd Hamdallah
ESEsraa Alsayed Sibaey
Esraa Alsayed Sibaey
AHAlyaa Sayed Hussein
Alyaa Sayed Hussein
MAMuhammad Abdelaziz
Muhammad Abdelaziz
ANAnas Nourelden
Anas Nourelden

20 May 2022 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
MZMohamed Sayed Zaazouee
Mohamed Sayed Zaazouee
AHAboalmagd Hamdallah
Aboalmagd Hamdallah
SHSara Kamel Helmy
Sara Kamel Helmy
EHElfatih A. Hasabo
Elfatih A. Hasabo
ASAhmed Kamal Sayed
Ahmed Kamal Sayed
ANAnas Nourelden
Anas Nourelden

1 April 2021 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
SASomia Alshafie
Somia Alshafie
GEGhidaa Osama El-Helw
Ghidaa Osama El-Helw
AFAya M. Fayoud
Aya M. Fayoud
AEAsmaa Ahmed Elrashedy
Asmaa Ahmed Elrashedy
MGMohamed Ibrahim Gbreel
Mohamed Ibrahim Gbreel
ANAnas Nourelden
Anas Nourelden

28 December 2022 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
SMSajeda Ghassan Matar
Sajeda Ghassan Matar
ANAnas Nourelden
Anas Nourelden
AAAhmed Assar
Ahmed Assar
EBEshak I. Bahbah
Eshak I. Bahbah
AAAreej M. Alfryjat
Areej M. Alfryjat
IBIman A. Basheti
Iman A. Basheti
Background: There have been varying reports on the potential occurrence and severity of changes to menstruation including the median cycle length, days of bleeding, bleeding heaviness, and menstrual pain, following receipt of COVID‐19 vaccinations. We aimed to assess potential postvaccination menstrual changes in women residing in the Middle East.Methods: We implemented a cross‐sectional online survey‐based study. Data about the participants' demographic characteristics, menstruation experience, and vaccination status were collected and analyzed among six Arab countries.Results: Among 4942 menstruating females included in this study, females who had received one or more doses of COVID‐19 vaccination reported a higher frequency of back pain, nausea, tiredness, pelvic pain with periods, unprescribed analgesics use, and passage of loose stools. They also reported higher scores describing average and worst menstrual pain. Fully vaccinated females reported heavier flow and more days of bleeding.Conclusion: Our findings indicate that COVID‐19 vaccine may have an effect on menstruation in terms of menstrual pain and bleeding heaviness. The evidence needs to be further investigated in longitudinal studies.

8 April 2021 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
MAMohamed Abdo
Mohamed Abdo
AHAhmed Hanbal
Ahmed Hanbal
MAMoamen Mostafa Asla
Moamen Mostafa Asla
AIAnas Ishqair
Anas Ishqair
MAMerana Alfar
Merana Alfar
MZMohamed Sayed Zaazouee
Mohamed Sayed Zaazouee
Ventilated preterm infants are exposed to deviations from the intended arterial oxygen saturation range. Therefore, an automated control system was developed to rapidly modulate the fraction of ins...